Skip to content

Ketamine in Chronic Kid's (KiCK) Pain

TerminatedPhase 2NCT01755169
View the official record on ClinicalTrials.gov

Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.

This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.

Brief summary (from the registry)

This study is designed to select the most tolerable dose of oral ketamine for children with chronic pain. Children will be given either placebo or one of three dosages of oral ketamine for 2 weeks. The dosage that is most tolerable will be selected for further study.

Study details

Official title
Ketamine in Chronic Kid's (KiCK) Pain
Conditions
Sponsor
Medical University of South Carolina
Start date
2013-01
Primary completion
2015-05
Sex
All
Age range
from 8 Years to 20 Years
Results posted
Yes, on ClinicalTrials.gov
Countries
United States
Total sites listed
1

Eligibility criteria

Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Subject, parent, or guardian willing and able to give informed consent * NRS for pain over the past 24 hours \>4 at baseline * Chronic pain, which has been present for \>3 months, or persisting longer than is normal for the underlying diagnosis * Chronic pain related to physiologic diagnoses including but not limited to: cancer, rheumatologic disease, sickle cell anemia, cystic fibrosis, pancreatitis, and neuromuscular disease (e.g. Duchenne muscular dystrophy) * Able to tolerate and cooperate with neurocognitive assessment * Age 8-20 years old Exclusion Criteria: * If they are known or suspected to have drug addiction * Uncontrolled psychiatric disorder such as depression, schizophrenia, or bipolar disorder * Uncontrolled hypertension * Known liver disease or elevation of AST or ALT greater than 3 times the upper limit of normal. * Previous intolerance or allergic reaction to ketamine * Pregnancy * Use of CYP3A4 inhibitors or inducers within the 2-week period prior the study drug administration or within 5 half-lives of the respective medication, whichever is longer, until study conclusion. * Consumption of grapefruit or grapefruit products from at least 2 weeks prior to study drug administration until study conclusion.

Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT01755169